ABCL vs MCK: fair value comparison
AbCellera Biologics Inc. and McKesson Corporation · Updated 2026-10-19
ABCL has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, MCK currently ranks higher by quality score.
| ABCL | MCK | |
|---|---|---|
| Verdict | No estimate yet | Fairly valued |
| Last price | $11.80 | $938.84 |
| 12-month range | $2.78–$14.82 | $725.17–$1,004.84 |
| Rank by discount to fair value | — | #68 of 108 Healthcare |
| Rank by quality score | #172 of 301 Healthcare | #171 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Declining | Strong |
| RSI zone | Neutral | Overbought |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Fairly Valued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: ABCL fair value analysis · MCK fair value analysis